- Home
- BATL vs PLUR Comparison
BATL vs PLUR Comparison
Compare BATL & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BATL | PLUR |
|---|---|---|
| Founded | 1987 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 25.5M |
| IPO Year | 2004 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BATL | PLUR |
|---|---|---|
| Price | $1.32 | $2.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 15.0M | 10.1K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.56 | 10.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,043,000.00 | $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $1.00 | $1.99 |
| 52 Week High | $29.70 | $5.96 |
Technical Indicators
Market Signals| Indicator | BATL | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 37.48 |
| Support Level | $1.06 | N/A |
| Resistance Level | $1.32 | $2.58 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 11.86 | 22.73 |
Price Performance
Historical ComparisonAbout BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.